Home/Pipeline/ARD-885

ARD-885

Rheumatoid Arthritis, Systemic Lupus Erythematosus

Phase 2In preparation

Key Facts

Indication

Rheumatoid Arthritis, Systemic Lupus Erythematosus

Phase

Phase 2

Status

In preparation

Company

Artivila Therapeutics

About Artivila Therapeutics

Clinical-stage biotech using AI-powered drug discovery to develop first-in-class therapies for autoimmune diseases, neurodegenerative disorders, and cancers.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Rheumatoid Arthritis, Systemic Lupus Erythematosus Drugs

Drug	Company	Phase	Status
ADSC Therapy for Autoimmune Conditions	A4Cell	Pre-clinical	Inferred R&D